Pretoria.

Methods	Randomised trial.
Participants	148 premenopusal women with node positive breast cancer were randomised. Two postmenopausal women were randomised. 145 women were included in the disease free survival and overall survival analyses (excluding one who refused therapy and two who were lost to follow up).
Interventions	Patients were randomised to CMF (cyclophosphamide 100mg/m2 orally on d1‐14, methotrexate 40mg/m2 iv d1 and d8, and 5‐flourouracil 600mg/m2 iv d1 and d8) every 28 days for 6 cycles (n=75) or CMF and depo‐buserelin (6.6mg implants monthly) (n=72).
Outcomes	Primary outcomes: disease‐free survival and overall survival.
Notes	Global quality rating: not assigned.
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment (selection bias)	Unclear risk	B ‐ Unclear